October 5, 2021
RegMed Investors’ (RMi) closing bell: a barely upside turnaround
October 4, 2021
RegMed Investors’ (RMi) closing bell: sector was under heavy pressure, with a muddy path forward for sector equities
October 1, 2021
RegMed Investors’ (RMi) closing bell: Back from the depths to close positive
September 30, 2021
RegMed Investors’ (RMi) closing bell: sector closes the month with a slip and fall
September 29, 2021
RegMed Investors’ (RMi) closing bell: called it volatile and liquid this a.m., it was
September 28, 2021
RegMed Investors’ (RMi) closing bell: Déjà vu, the deep end
September 27, 2021
RegMed Investors’ (RMi) closing bell: risks are mounting as sentiment seems AWOL
September 24, 2021
RegMed Investors’ (RMi) closing bell: this morning’s “twitch” came to fruition
September 23, 2021
RegMed Investors’ (RMi) closing bell: lucky sector up day with low volume but, risk is still lurking
September 22, 2021
RegMed Investors’ (RMi) closing bell: back in the green after a volatile session
September 21, 2021
RegMed Investors’ (RMi) closing bell: a buying opportunity for the stem cell and gene therapy sector
September 17, 2021
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector rebounds from the quadruple witching swallowing fear
September 16, 2021
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector share pricing beat-back quadruple witching
September 15, 2021
RegMed Investors’ (RMi) closing bell: follow the bouncing share pricings
September 14, 2021
RegMed Investors’ (RMi) closing bell: key word for today’s session - fragility
September 13, 2021
RegMed Investors’ (RMi) closing bell: sector action, sputtering
September 10, 2021
RegMed Investors’ (RMi) closing bell: losses accelerated as the session closed
September 9, 2021
RegMed Investors’ (RMi) closing bell: sentiment loads its soppiness
September 8, 2021
RegMed Investors’ (RMi) closing bell: another cell and gene therapy session of drip, drip down on thin volume
September 7, 2021
RegMed Investors’ (RMi) closing bell: drip, drip down
September 6, 2021
Happy Labor Day …
September 3, 2021
RegMed Investors’ (RMi) closing bell: the cell and gene therapy highs hit the wall and bounced to the downside
September 2, 2021
RegMed Investors’ (RMi) closing bell: strolling to the upside on low volume
September 1, 2021
RegMed Investors’ (RMi) closing bell: are we in a goldilocks continuum?
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.